Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.news

BAVENCIO Continues to Strengthen Its Position in the Immuno-Oncology Landscape |…

Pfizer/Merck/EMD Sereno's BAVENCIO (avelumab) Overview Pfizer/Merck/EMD Sereno's BAVENCIO (avelumab) Overview BAVENCIO is a human antibody targeting programmed death ligand-1 (PD-L1). Preclinical studies have demonstrated its ability to activate both adaptive and innate immune responses. By inhibiting the interaction between PD-L1 and PD-1 receptors, BAVENCIO helps restore T cell-mediated antitumor immunity in preclinical models. InNovember 2014, Merck KGaA, Darmstadt,Germany, and...

Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the…

All resolutions approved by bondholders Closing of Royalty Financing and receipt of first €130 million instalment expected shortlyUpon closing of the Royalty Financing, GENFIT will implement the Repurchase of the 2025 OCEANEs and pay the Consent Fee Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), March 10, 2025-GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and...

Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on…

NyxoahtoReleaseFourthQuarter and Financial Year 2024FinancialResults on March 13, 2025Mont-Saint-Guibert, Belgium – Monday, March 10, 2025, 10:05pm CET / 5:05pm ET– Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the fourth quarter and financial year 2024 on Thursday, March 13, 2025...

Endo Reschedules Release of Fourth Quarter and Full Year 2024 Earnings Results…

About EndoEndo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn. About EndoEndo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate...

Syngene Acquires its First Manufacturing Facility in the US

The state-of-the-art biologics facility, acquired by Syngene USA Inc., a wholly owned subsidiary of Syngene, from Emergent Manufacturing Operations Baltimore, LLC (a subsidiary of Emergent BioSolutions Inc.), will expand Syngene's growing global biologics footprint to better serve its customers across both human and animal health market segments. The new site will increase Syngene's total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing…

Clario Enters into Definitive Agreement to Acquire WCG's eCOA Business

Electronic clinical outcomes assessments (eCOA), in addition to paper assessments, are used to evaluate the safety and efficacy of new drugs by measuring how a clinical trial participant feels or functions. WCG's eCOA operations offer robust, full-service clinical expertise and specialized functionality, particularly in neurology, psychiatry, neuropathic pain, and rare diseases. Electronic clinical outcomes assessments (eCOA), in addition to paper assessments, are used to evaluate the...

EssilorLuxottica: 2024 Universal Registration Document filed

2024 Universal Registration Document filedParis, France (10 March 2025)– EssilorLuxottica announces the availability of its 2024 Universal Registration Document, in accordance with applicable regulation. The French version of this document, prepared in ESEF format (European Single Electronic Format), was filed with the Autorité des Marchés Financiers (AMF, the French market regulator) on March 10, 2025 under the reference D.25-0081. The Universal Registration Document includes, in...

Wingderm® Presents at the 2025 AAD Annual Meeting, Strengthening Its Presence in…

Wingderm® showcased its advanced laser devices. Lasermach features 755nm, 808nm, and 1064nm wavelengths, effectively targeting melanin at different follicle depths for optimal and long-lasting results. The 1550nm non-ablative fractional laser, equipped with advanced optical scanning tracking technology, penetrates deep into the skin without damaging the epidermis, stimulating collagen regeneration for skin resurfacing. These proven technologies have gained widespread recognition. Wingderm®...

Orion Corporation: Transfer of 191,911 own B shares on 10 March 2025

ORION CORPORATIONSTOCK EXCHANGE RELEASE – CHANGES IN COMPANY'S OWN SHARES 10 MARCH 2025 at 19.00 EET Orion Corporation: Transfer of 191,911 own B shares on 10 March 2025 In accordance with a decision by the Board of Directors, Orion Corporation has on 10 March 2025 transferred altogether 191,911 Orion Corporation B shares held by the company as a share reward for earning period 2022–2024 and a reward for commitment part to the persons belonging to the Share-based Incentive...

Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2…

Previously, a Phase 1 study (NCT06548997) of bofanglutide injection demonstrated good safety and tolerability in US subjects, along with promising glucose-lowering and weight-loss potential[1]. The initiation of head-to-head clinical study for bofanglutide versus tirzepatide, marking a new phase in Gan & Lee's GLP-1 innovation. This milestone underscores the company's ambition to challenge the leading GLP-1 therapy in the global market for weight management, aiming to provide a better…

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities…

ORION CORPORATIONSTOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 10 March 2025 at 17.00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly or indirectly by BlackRock, Inc. and its funds decreased on 7 March 2025 below five (5) per cent of Orion...

Dental Implants and Prosthetics Market worth US$18.79 billion by 2030 with 8.4%…

Browse in-depth TOC on "Dental Implants and Prosthetics Market" Browse in-depth TOC on "Dental Implants and Prosthetics Market" 522 - Tables 65 - Figures 438 - Pages By Based on design,Tapered dental implants held the largest share in tapered dental implants, by design in 2024. They is due to the several advantages it holds over the parallel-walled dental implants. By creating a wedge effect during insertion, the tapered shape improves initial stability by gently...

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Company Announcement Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical development of HexaBody-CD38Data validates clinical potential of the HexaBody platform Genmab to host a conference call today at 5:00 PM CET / 4:00 PM GMT / 12:00 PM EDT COPENHAGEN, Denmark; March 10, 2025 –Genmab A/S(Nasdaq: GMAB) announced today that...

Transactions under Novonesis' share buyback program

Please read the announcement in PDF Attachment 2025_10_Share_buyback_program

Buyback of Class B shares in Essity during week 10, 2025

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat…

LONDON and NEW YORK, March10, 2025(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO ), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease, a multi-billion-dollar market, is pleased to announce the filing of its application for Fast Track designation with the U.S. Food and Drug Administration (FDA) for urcosimod (formerly...

Golden Helix Partners with the Danish Healthcare Regions to Drive Advancements…

Mette Christiansen, PhD, Head of the Diagnostic NGS Core Facility, MOMA, Aarhus University Hospital, shared her enthusiasm: "This multi-year agreement with Golden Helix ensures continued access to their advanced technology, which plays a key role in enhancing our diagnostic capabilities and treatment options. We look forward to building on our collaboration with Golden Helix to support improved patient care across Denmark and further advance genomic medicine." Mette Christiansen, PhD…

Orion Corporation: Managers' transactions – Outi Vaarala

Orion Corporation: Managers' transactions – Satu Ahomäki

Orion Corporation: Managers' transactions – Juhani Kankaanpää

Orion Corporation: Managers' transactions – Niclas Lindstedt

Interim analysis of 1-level BAGUERA®C IDE study meets threshold for…

Kuros Biosciences grows sales to CHF 75.6 million for 2024

Drug Launch Strategy Analysis: Success Story of Identifying First Launch…

BAVENCIO Continues to Strengthen Its Position in the Immuno-Oncology Landscape |…

Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the…

Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on…

Endo Reschedules Release of Fourth Quarter and Full Year 2024 Earnings Results…

Syngene Acquires its First Manufacturing Facility in the US

Clario Enters into Definitive Agreement to Acquire WCG's eCOA Business

EssilorLuxottica: 2024 Universal Registration Document filed

Wingderm® Presents at the 2025 AAD Annual Meeting, Strengthening Its Presence in…

Orion Corporation: Transfer of 191,911 own B shares on 10 March 2025

Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2…

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities…

Dental Implants and Prosthetics Market worth US$18.79 billion by 2030 with 8.4%…

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Transactions under Novonesis' share buyback program

Buyback of Class B shares in Essity during week 10, 2025

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat…

Golden Helix Partners with the Danish Healthcare Regions to Drive Advancements…